30 patents
Utility
Bifunctional Degraders of Hematopoietic Progenitor Kinase and Therapeutic Uses Thereof
18 Jan 24
The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by HPK1.
John Buell, Frederick Cohen, Ryan Pemberton, Hunter P. Shunatona, Lan Wang, Mark Edward Zak
Filed: 9 Nov 22
Utility
Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
9 Jan 24
The present invention relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway.
Daniel W. Robbins, Arthur T. Sands, Joel McIntosh, Jeffrey Mihalic, Jeffrey Wu, Daisuke Kato, Dahlia Weiss, Ge Peng
Filed: 28 Jul 22
Utility
Combination Therapies with CBL-B Inhibitor Compounds and Antiemetic Agents
28 Dec 23
The present disclosure relates to combination therapies with Cbl inhibitor compounds, and compositions and kits comprising combinations with the Cbl compounds.
Robert BROWN
Filed: 22 Jun 23
Utility
Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
21 Nov 23
This disclosure relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway.
Aileen Kelly, Arthur T. Sands
Filed: 3 Dec 20
Utility
Biomarkers for CBL, and Compositions and Methods for Their Use
9 Nov 23
Provided herein are biomarkers, compositions and methods for the measurement of CBL in samples, for instance in vivo samples.
Janine POWERS, Sarah Anne WHELAN
Filed: 24 Jul 23
Utility
Bifunctional Compounds for Degrading BTK Via Ubiquitin Proteosome Pathway
20 Jul 23
This disclosure relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway.
Aileen KELLY, Arthur T. SANDS
Filed: 10 Mar 23
Utility
Cyano Cyclobutyl Compounds for CBL-B Inhibition and Uses Thereof
6 Jul 23
Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed.
Arthur T. SANDS, Neil F. BENCE, Christoph W. ZAPF, Frederick COHEN, Chenbo WANG, Thomas CUMMINS, Hiroko TANAKA, Hunter SHUNATONA, Mario CARDOZO, Dahlia WEISS, Jennifa GOSLING
Filed: 19 Dec 22
Utility
Compounds for Inhibiting or Degrading Target Proteins, Compositions, Comprising the Same, Methods of Their Making, and Methods of Their Use
25 May 23
Provided herein are heterobifunctional compounds which find utility as modulators of targeted ubiquitination.
Eric Wegryzniak, Joel McIntosh, Daisuke Kato, Jeffrey Mihalic, Ge Peng
Filed: 16 Aug 22
Utility
Piperidinylpyrazine-carboxamide Compounds for Treating and Preventing Cancer and for Degrading BTK
18 May 23
This disclosure relates to BTK inhibitor compounds for treating or preventing cancer by daily oral dosing in human subjects in need thereof.
Robert J. Brown, Arthur T. Sands
Filed: 25 Oct 22
Utility
Substituted Benzyl-triazole Compounds for CBL-B Inhibition, and Further Uses Thereof
18 May 23
Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed.
Arthur T. SANDS, Neil F. Bence, Christoph W. Zapf, Frederick Cohen, Chenbo Wang, Thomas Cummins, Hiroko Tanaka, Hunter Shunatona, Mario Cardozo, Dahlia Weiss, Jennifa Gosling
Filed: 29 Jun 22
Utility
Bifunctional Degraders of INTERLEUKIN-1 Receptor-associated Kinases and Therapeutic Use Thereof
11 May 23
The present disclosure provides bifunctional compounds as IRAK4 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by IRAK4.
Wylie Solang PALMER, Jeffrey WU, Sheila ZIPFEL, Kerem OZBOYA, Dahlia WEISS
Filed: 19 Feb 21
Utility
Bifunctional Degraders of INTERLEUKIN-1 Receptor-associated Kinases and Therapeutic Use Thereof
20 Apr 23
The present disclosure provides bifunctional compounds as IRAK4 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by IRAK4.
Wylie Palmer, Jeffrey Wu, John Lee, Kerem Ozboya, Tim Kane
Filed: 18 Aug 22
Utility
Bifunctional Compounds for Degrading BTK Via Ubiquitin Proteosome Pathway
26 Jan 23
The present invention relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway.
Daniel W. ROBBINS, Arthur T. SANDS, Joel MCINTOSH, Jeffrey MIHALIC, Jeffrey WU, Daisuke KATO, Dahlia WEISS, Ge PENG
Filed: 28 Jul 22
Utility
Bifunctional Compounds for Grading BTK Via Ubiquitin Proteosome Pathway
26 Jan 23
Daniel W. ROBBINS, Ge PENG, Jeffrey MIHALIC, Arthur T. SANDS
Filed: 8 Nov 19
Utility
Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof
20 Dec 22
Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed.
Arthur T. Sands, Neil F. Bence, Christoph W. Zapf, Frederick Cohen, Chenbo Wang, Thomas Cummins, Hiroko Tanaka, Hunter Shunatona, Mario Cardozo, Dahlia Weiss, Jennifa Gosling
Filed: 15 May 20
Utility
Urea, Amide, and Substituted Heteroaryl Compounds for CBL-B Inhibition
8 Dec 22
Arthur T. SANDS, Neil F. BENCE, Christoph W. ZAPF, Frederick COHEN, Chenbo WANG, Thomas CUMMINS, Hiroko TANAKA, Morgan LAWRENZ, Mario CARDOZO, Dahlia WEISS, Jennifa GOSLING
Filed: 27 Jul 20
Utility
3-SUBSTITUTED Piperidine Compounds for CBL-B Inhibition, and Use Thereof
1 Dec 22
Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed.
Arthur T. SANDS, Neil F. BENCE, Christoph W. ZAPF, Frederick COHEN, Chenbo WANG, Thomas CUMMINS, Hiroko TANAKA, Hunter SHUNATONA, Mario CARDOZO, Dahlia WEISS, Jennifa GOSLING
Filed: 13 Jul 22
Utility
Combination Therapies with CBL-B Inhibitor Compounds
27 Oct 22
The present disclosure relates to combination therapies with Cbl-b inhibitor compounds, and compositions and kits comprising combinations with the Cbl-b compounds.
Cristiana GUIDUCCI, Marilena GALLOTTA
Filed: 8 Apr 22
Utility
Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
25 Oct 22
The present invention relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway.
Daniel W. Robbins, Arthur T. Sands, Joel McIntosh, Jeffrey Mihalic, Jeffrey Wu, Daisuke Kato, Dahlia Weiss, Ge Peng
Filed: 14 Oct 19
Utility
Inhibitors of CBL-B and Methods of Use Thereof
13 Oct 22
Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed.
Paul A. BARSANTI, Neil F. BENCE, Jennifa GOSLING, Anjanabha SAHA, Asad M TAHERBHOY, Christoph W. ZAPF, Kathleen BOYLE, Mario CARDOZO, Jeffrey MIHALIC, Morgan LAWRENZ, Mark GALLOP, Jilliane BRUFFEY, Thomas CUMMINS, Daniel ROBBINS, Hiroko TANAKA, Chenbo WANG, Frederick COHEN, Wylie PALMER, Arthur T. SANDS, Hunter SHUNATONA
Filed: 25 Jan 19